Clodronate inhibits adrenocortical cell proliferation and P450c21 activity

Journal of Endocrinology

Volumn 174, Issue 3, 2002, Pages 509-516

  Fassnacht, M ^a   Franke, A ^a   Dettling, A ^a   Hahner, S ^a   Zink, M ^a   Wudy, S ^a   Allolio, B ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CORTICOTROPIN; CORTODOXONE; HYDROCORTISONE; HYDROXYPROGESTERONE; PAMIDRONIC ACID; STEROID 21 MONOOXYGENASE;

ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX CELL; ANIMAL CELL; APOPTOSIS; ARTICLE; CATTLE; CELL COUNT; CELL PROLIFERATION; CELL TYPE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; GAS CHROMATOGRAPHY; HORMONE RELEASE; HUMAN; HUMAN CELL; ISOTOPE DILUTION ASSAY; MASS SPECTROMETRY; NECROSIS; NONHUMAN; PRIORITY JOURNAL; STEROIDOGENESIS;

ADRENAL CORTEX; ANIMALS; ANTIMETABOLITES; CATTLE; CELL DIVISION; CLODRONIC ACID; DEPRESSION, CHEMICAL; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; STEROID 21-HYDROXYLASE; TUMOR CELLS, CULTURED;

EID: 0036740514     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1740509     Document Type: Article

References (57)

1. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J & Lichtenstein A 1998 In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12 220-229.
2. van Beek E, Pieterman E, Cohen L, Lowik C & Papapoulos S 1999a Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochemical and Biophysical Research Communications 264 108-111.
3. van Beek E, Pieterman E, Cohen L, Lowik C & Papapoulos S 1999b Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochemical and Biophysical Research Communications 255 491-494.
4. van Beek ER, Losvik CW & Papapoulos SE 2002 Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone 30 64-70.
5. Benford HL, Frith JC, Auriola S, Monkkonen J & Rogers MJ 1999 Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Molecular Pharmacology 56 131-140.
6. Berenson JR 1997 Bisphosphonates in multiple myeloma. Cancer 80 1661-1667.
7. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ et al. 1996. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myelonia. Myeloma Aredia Study Group. New England Journal of Medicine 334 488-493.
8. Busch M, Rave-Frank M, Hille A & Duhmke E 1998 Influence of clodronate on breast cancer cells in vitro. European Journal of Medical Research 3 427-431.
9. Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A & Rogers MJ 2000 Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. Journal of Bone and Mineral Research 15 1467-1476.
10. Coxon FP, Helfrich MH, Larijani B, Muzylak M, Dunford JE, Marshall D, McKinnon AD, Nesbitt SA, Norton MA, Seabra MC et al. 2001 Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. Journal of Biological Chemistry 276 48213-48222.
11. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M & Bastert G 1998 Reduction in new metastases in breast cancer with adjuvant clodronate treatment. New England Journal of Medicine 339 357-363.
12. Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M & Glasmacher A 2001 Bisphosphonates in multiple myeloma (Cochrane Review). Cochrane Database of Systematic Reviews 4 CD003188.
13. Duerst RE & Frantz CN 1985 A sensitive assay of cytotoxicity applicable to mixed cell populations. Journal of Immunological Methods 82 39-46.
14. Fassnacht M, Beuschlein F, Vay S, Mora P, Allolio B & Reincke M 1998 Aminoglutethimide suppresses adrenocorticotropin receptor expression in the NCI-h295 adrenocortical tumor cell line. Journal of Endocrinology 159 35-42.
15. Fassnacht M, Halner S, Beuschlein F, Klink A, Reincke M & Allolio B 2000 New mechanisms of adrenostatic compounds in a human adrenocortical cancer cell line. European Journal of Clinical Investigation 30 76-82.
16. Fisher JE, Rodan GA & Reszka AA 2000 In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 141 4793-4796.
17. Fleisch H 1998 Bisphosphonates: mechanisms of action. Endocrine Reviews 19 80-100.
18. Frith JC, Monkkonen, J, Blackburn GM, Russell RG & Rogers MJ 1997 Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. Journal of Bone and Mineral Research 12 1358-1367.
19. Fromigue O, Lagneaux L & Body JJ 2000 Bisphosphonates induce breast cancer cell death in vitro. Journal of Bone and Mineral Research 15 2211-2221.
20. Gazdar AF, Oie HK, Shackleton CH, Chen TR, Triche TJ, Myers CE, Chrousos GP, Brennan MF, Stein CA, La Rocca RV 1990 Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Research 50 5488-5496.
21. Halasy-Nagy JM, Rodan GA & Reszka AA 2001 Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 29 553-559.
22. Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang Peng J, Rogan AM, Green WR & Ozols RF 1983 Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Research 43 5379-5389.
23. Hanhijarvi H, Elomaa I, Karlsson M & Lauren L 1989 Pharmacokinetics of disodium clodronate after daily intravenous infusions during five consecutive days. International Journal of Clinical Pharmacology, Therapy and Toxicology 27 602-606.
24. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA & Murphy GP 1983 LNCaP model of human prostatic carcinoma. Cancer Research 43 1809-1818.
25. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J & Knight RD 1996 Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lyric bone metastases. Protocol 19, Aredia Breast Cancer Study Group. New England Journal of Medicine 335 1785-1791.
26. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman J & Knight RD et al. 1998 Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19, Aredia Breast Cancer Study Group. Journal of Clinical Oncology 16 2038-2044.
27. Hurst M & Noble S 1999 Clodronate: a review of its use in breast cancer. Drugs Aging 15 143-167.
28. Kanis J & McCloskey E 2000. Bisphosphonates in multiple myeloma. Cancer 88 3022-3032.
29. von Kleist S, Chany E, Burtin P, King M & Fogh J 1975 Immunohistology of the antigenic pattern of a continuous cell line from a human colon tumor. Journal of the National Cancer Institute 55 555-560.
30. Le Roy C, Li JY, Stocco DM, Langlois D & Saez JM 2000 Regulation by adrenocorticotropin (ACTH), angiotensin II, transforming growth factor-beta, and insulin-like growth factor I of bovine adrenal cell steroidogenic capacity and expression of ACTH receptor, steroidogenic acute regulatory protein, cytochrome P450c 17, and 3 beta-hydroxysteroid dehydrogenase. Endocrinology 141 1599-1607.
31. Lee MV, Fong EM, Singer FR & Guenette RS 2001 Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Research 61 2602-2608.
32. Lipton A 2000 Bisphosphonates and breast carcinoma: present and future. Cancer 88 3033-3037.
33. Luckman SP, Coxon FP, Ebetino FH & Russell RG 1998a Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. Journal of Bone and Mineral Research 13 1668-1678.
34. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G & Rogers MJ 1998b Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Journal of Bone and Mineral Research 13 581-589.
35. Mason, JI, Bird IM & Rainey WE 1995 Adrenal androgen biosynthesis with special attention to P450c17. Annals of the New York Academy of Sciences 774 47-58.
36. Mundy GR & Yoneda T 1998 Bisphosphonates as anticancer drugs. New England Journal of Medicne 339 398-400.
37. Nader S, Hickey K, Sellin R & Damann N 1983 Adrenocortical carcinomas: a study of 77 cases. Cancer 52 707-713.
38. Pavlakis N & Stockler M 2002 Bisphosphonates in breast cancer (Cochrane Review). Cochrane Database of Systematic Reviews 1 CD003474.
39. Rainey WE, Bird IM, Sawetawan C, Hanley NA, McCarthy JL, McGee EA, Wester R & Mason JI 1993 Regulation of human adrenal carcinoma cell (NCI-H295) production of C19 steroids. Journal of Clinical Endocrinology and Metabolism 77 731-737.
40. Rainey WE, Bird IM & Mason JI 1994 The NCI-H295 cell line: a pluripotent model for human adrenocortical studies. Molecular and Cellular Endocrinology 100 45-50.
41. Reszka AA, Halasy-Nagy JM, Masarachia PJ & Rodan GA 1999 Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. Journal of Biological Chemistry 274 34967-34973.
42. Rodan GA & Fleisch HA 1996 Bisphosphonates: mechanisms of action. Journal of Clinical Investigation 97 2692-2696.
43. Rogers M, Gordon S, Benford H, Coxon F, Luckman S, Monkkonen J & Frith J 2000 Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 2961-2978.
44. Russell R & Rogers M 1999 Bisphosphonates: from the laboratory to the clinic and back again. Bone 25 97-106.
45. Sahni M, Guenther HL, Fleisch H, Collin P & Martin TJ 1993 Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. Journal of Clinical Investigation 91 2004-2011.
46. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E & Rodan GA 1991 Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. Journal of Clinical Investigation 88 2095-2105.
47. Schteingart DE & Homan D 2001 Management of adrenal cancer. In Adrenal Disorders, pp 231-248. Eds AN Margions & GP Chrousos. Totowa, New Jersey: Humana Press Inc.
48. Senaratne S, Pirianov G, Mansi J, Arnett T & Colston K 2000 Bisphosphonates induce apoptosis in human breast cancer cell lines. British Journal of Cancer 82 1459-1468.
49. Shipman CM, Rogers MJ, Apperley JF, Russell RG & Croucher PI 1997 Bisphosphonates induce apoptosis in human myeloma, cell lines: a novel anti-tumour activity. British Journal of Haematology 98 665-672.
50. Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W & van Valen F 2001 The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 12 459-465.
51. Soreide JA, Brabrand K & Thoresen SO 1992 Adrenal cortical carcinoma in Norway 1970-1984. World Journal of Surgery 16 663-667.
52. Staels B, Hum DW & Miller WL 1993 Regulation of steroidogenesis in NCI-H295 cells: a cellular model of the human fetal adrenal. Molecular Endocrinology 7 423-433.
53. Weber MM & Michl P 1996 Primary culture of bovine and human adult adrenocortical cells. Endocrine Methods 17 393-416.
54. Westley B & Rochefort H 1980 A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell 20 353-362.
55. Wudy SA, Homoki J & Teller WM 2001 Clinical steroid analysis by gas-chromatography-mass spectrometry. In Current Practice of Gas Chromatography-Mass Spectrometry, pp 309-339. Ed WMA Niessen. New York, Basel: Marcel Dekker.
56. Yakatan G, Poynor W, Talbert R, Floyd B, Slough C, Ampulski R & Benedict J 1982 Clodronate kinetics and bioavailability. Clinical Pharmacology and Therapeutics 31 402-410.
57. Ylitalo P, Holli K, Monkkonen J, Elo HA, Juhakoski A, Liukko-Sipi S & Ylitalo R 1999 Comparison of pharmacokinetics of clodronate after single and repeated doses. International Journal of Clinical Pharmacology and Therapeutics 37 294-300.